Paysign: 3 Key Takeaways for Long-Term Investors
Plasma donor card revenue is shrinking as Paysign shifts toward patient affordability, so the margin story depends on how fast that pivot plays out.
Paysign reported a 43% year-over-year revenue increase to $30.8 million in its third-quarter 2026 earnings call, driven by expansion in its pharmaceutical copay assistance business. The company's patient affordability solutions are proving to be a growth engine, with revenue in this segment growing 110% year-over-year to $16.6 million.
Management highlighted the importance of protecting client budgets through dynamic business rules software, which insulates clients from costs that co-pay accumulators would otherwise absorb. With zero bank debt and $34.5 million in cash, Paysign is allocating capital to high-margin patient-assistance features while expanding its core processing operations.
Brief written by urgent.news from Motley Fool's own syndicated text. Machine-written — may contain errors; check the original before relying on it.